

## BIOMEDICA EZ4U - References / Publications

### **Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes.**

Kallus, S., Uhlik, L., van Schoonhoven, S., Pelivan, K., Berger, W., Enyedy, É.A., Hofmann, T., Heffeter, P., Kowol, C.R., Keppler, B.K., 2019. *Journal of Inorganic Biochemistry* 190, 85–97.

<https://doi.org/10.1016/j.jinorgbio.2018.10.006>

### **Surface functionalization via PEO coating and RGD peptide for nanostructured titanium implants and their in vitro assessment.**

Parfenov, E.V., Parfenova, L.V., Dyakonov, G.S., Danilko, K.V., Mukaeva, V.R., Farrakhov, R.G., Lukina, E.S., Valiev, R.Z., 2019. *Surface and Coatings Technology* 357, 669–683.

<https://doi.org/10.1016/j.surfcoat.2018.10.068>

### **First homology model of Plasmodium falciparum glucose-6-phosphate dehydrogenase: Discovery of selective substrate analog-based inhibitors as novel antimalarial agents.**

Alencar, N., Sola, I., Linares, M., Juárez-Jiménez, J., Pont, C., Viayna, A., Vílchez, D., Sampedro, C., Abad, P., Pérez-Benavente, S., Lameira, J., Bautista, J.M., Muñoz-Torrero, D., Luque, F.J., 2018. *Eur J Med Chem* 146, 108–122.

<https://doi.org/10.1016/j.ejmech.2018.01.044>

PMID: 29407943

### **A doxorubicin loaded colloidal delivery system for the intravesical therapy of non-muscle invasive bladder cancer using wheat germ agglutinin as targeter.**

Apfelthaler, C., Skoll, K., Ciola, R., Gabor, F., Wirth, M., 2018. *Eur J Pharm Biopharm* 130, 177–184.

<https://doi.org/10.1016/j.ejpb.2018.06.028>

PMID: 29960015

### **Bai Hu Tang, Si Ni Tang, and Xue Bi Tang amplify pro-inflammatory activities and reduce apoptosis in endothelial cells in a cell culture model of sepsis.**

Brislinger, D., Daxböck, C., Roßmanith, E., Stückler, M., Lang, I., Falkenhagen, D., 2018. *J Ethnopharmacol* 225, 309–318.

<https://doi.org/10.1016/j.jep.2018.07.021>

PMID: 30036577

### **Exceptional in vivo catabolism of neurodegeneration-related aggregates.**

Datki, Z., Olah, Z., Hortobagyi, T., Macsai, L., Zsuga, K., Fulop, L., Bozso, Z., Galik, B., Acs, E., Foldi, A., Szarvas, A., Kalman, J., 2018. *Acta Neuropathologica Communications* 6, 6.

<https://doi.org/10.1186/s40478-018-0507-3>

**Protein nanoparticles are nontoxic, tuneable cell stressors.**

de Pinho Favaro, M.T., Sánchez-García, L., Sánchez-Chardi, A., Roldán, M., Unzueta, U., Serna, N., Cano-Garrido, O., Azzoni, A.R., Ferrer-Miralles, N., Villaverde, A., Vázquez, E., 2018. *Nanomedicine (Lond)* 13, 255–268.

<https://doi.org/10.2217/nnm-2017-0294>

PMID: 29338574

**Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1.**

Dufour, A.M., Alvarez, M., Russo, B., Chizzolini, C., 2018. *Front Immunol* 9, 1865.

<https://doi.org/10.3389/fimmu.2018.01865>

PMID: 30150989; PMCID: PMC6099180

**Interleukin-4 induces a CD44<sup>high</sup> /CD49b<sup>high</sup> PC3 subpopulation with tumor-initiating characteristics.**

Erb, H.H.H., Guggenberger, F., Santer, F.R., Culig, Z., 2018. *J. Cell. Biochem.* 119, 4103–4112.

<https://doi.org/10.1002/jcb.26607>

PMID: 29236307; PMCID: PMC5900863

**Naked mole rat cells display more efficient excision repair than mouse cells.**

Evdokimov, A., Kutuzov, M., Petrusheva, I., Lukjanchikova, N., Kashina, E., Kolova, E., Zemerova, T., Romanenko, S., Perelman, P., Prokopov, D., Seluanov, A., Gorbunova, V., Graphodatsky, A., Trifonov, V., Khodyreva, S., Lavrik, O., 2018. *Aging (Albany NY)* 10, 1454–1473.

<https://doi.org/10.18632/aging.101482>

PMID: 29930219; PMCID: PMC6046242

**Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.**

Heilos, D., Röhrli, C., Pirker, C., Englinger, B., Baier, D., Mohr, T., Schwaiger, M., Iqbal, S.M., van Schoonhoven, S., Klavins, K., Eberhart, T., Windberger, U., Taibon, J., Sturm, S., Stuppner, H., Koellensperger, G., Dornetshuber-Fleiss, R., Jäger, W., Lemmens-Gruber, R., Berger, W., 2018. *Oncotarget* 9, 25661–25680.

<https://doi.org/10.18632/oncotarget.25432>

PMID: 29876015; PMCID: PMC5986646

**Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes.**

Kallus, S., Uhlik, L., van Schoonhoven, S., Pelivan, K., Berger, W., Enyedy, É.A., Hofmann, T., Heffeter, P., Kowol, C.R., Keppler, B.K., 2018. *J. Inorg. Biochem.* 190, 85–97.

<https://doi.org/10.1016/j.jinorgbio.2018.10.006>

PMID: 30384010

**Comb-like PEG-containing polymeric composition as low toxic drug nanocarrier.**

Kobylińska, L., Patereha, I., Finiuk, N., Mitina, N., Riabtseva, A., Kotsyumbas, I., Stoika, R., Zaichenko, A., Vari, S.G., 2018. *Cancer Nanotechnology* 9, 11.  
<https://doi.org/10.1186/s12645-018-0045-5>

**MF-8, a novel promising arylpiperazine-hydantoin based 5-HT7 receptor antagonist: In vitro drug-likeness studies and in vivo pharmacological evaluation.**

Latacz, G., Lubelska, A., Jastrzębska-Więsek, M., Partyka, A., Kucwaj-Brysz, K., Wesołowska, A., Kieć-Kononowicz, K., Handzlik, J., 2018. *Bioorg. Med. Chem. Lett.* 28, 878–883.  
<https://doi.org/10.1016/j.bmcl.2018.02.003>  
PMID: 29439902

**Antioxidative 1,4-Dihydropyridine Derivatives Modulate Oxidative Stress and Growth of Human Osteoblast-Like Cells In Vitro.**

Milkovic, L., Vukovic, T., Zarkovic, N., Tatzber, F., Bisenieks, E., Kalme, Z., Bruvere, I., Ogle, Z., Poikans, J., Velená, A., Duburs, G., 2018. *Antioxidants (Basel)* 7.  
<https://doi.org/10.3390/antiox7090123>  
PMID: 30235855; PMCID: PMC6162383

**Anti-tumour active gold(i), palladium(ii) and ruthenium(ii) complexes with thio- and selenoureato ligands: a comparative study.**

Molter, A., Kathrein, S., Kircher, B., Mohr, F., 2018. *Dalton Trans* 47, 5055–5064.  
<https://doi.org/10.1039/C7DT04180B>  
PMID: 29561018

**Reversible opening of the blood-brain barrier by claudin-5-binding variants of Clostridium perfringens enterotoxin's claudin-binding domain.**

Neuhaus, W., Piontek, A., Protze, J., Eichner, M., Mahringer, A., Subileau, E.-A., Lee, I.-F.M., Schulzke, J.D., Krause, G., Piontek, J., 2018. *Biomaterials* 161, 129–143.  
<https://doi.org/10.1016/j.biomaterials.2018.01.028>  
PMID: 29421550

**The involvement of NK1 and Y2 receptor in the development of laser-induced CNVs in C57Bl/6N mice.**

Nowosielski, Y., Haas, G., Seifarth, C., Wohlfarter, W., Tasan, R., Verius, M., Troger, J., Bechrakis, N., 2018. *Exp. Eye Res.* 177, 87–95.  
<https://doi.org/10.1016/j.exer.2018.07.030>  
PMID: 30076797

**Chlorinated cobalt alkyne complexes derived from acetylsalicylic acid as new specific antitumor agents.**

Obermoser, V., Baecker, D., Schuster, C., Braun, V., Kircher, B., Gust, R., 2018. *Dalton Transactions* 47, 4341–4351.  
<https://doi.org/10.1039/C7DT04790H>

**Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.**

Rath, B., Hochmair, M., Plangger, A., Hamilton, G., 2018. *Mar Drugs* 16.  
<https://doi.org/10.3390/md16100383>  
PMID: 30322180; PMCID: PMC6213142

**Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.**

Royo, S., Schirmeister, T., Kaiser, M., Jung, S., Rodríguez, S., Bautista, J.M., González, F.V., 2018. *Bioorg. Med. Chem.* 26, 4624–4634.  
<https://doi.org/10.1016/j.bmc.2018.07.015>  
PMID: 30037754

**A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.**

Schelch, K., Kirschner, M.B., Williams, M., Cheng, Y.Y., van Zandwijk, N., Grusch, M., Reid, G., 2018. *Mol Oncol* 12, 58–73.  
<https://doi.org/10.1002/1878-0261.12150>  
PMID: 29094504; PMCID: PMC5748487

**TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.**

Spiegel-Kreinecker, S., Lötsch, D., Neumayer, K., Kastler, L., Gojo, J., Pirker, C., Pichler, J., Weis, S., Kumar, R., Webersinke, G., Gruber, A., Berger, W., 2018. *Neuro-Oncology*.  
<https://doi.org/10.1093/neuonc/noy104>

**The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy.**

Syring, I., Weiten, R., Müller, T., Schmidt, D., Steiner, S., Kristiansen, G., Müller, S.C., Ellinger, J., 2018. *Oncology Letters* 16, 3013–3021.  
<https://doi.org/10.3892/ol.2018.9014>

**A preclinical model for studying herpes simplex virus infection.**

Tajpara, P., Mildner, M., Schmidt, R., Vierhapper, M., Matiasek, J., Popow-Kraupp, T., Schuster, C., Elbe-Bürger, A., 2018. *J. Invest. Dermatol.*  
<https://doi.org/10.1016/j.jid.2018.08.034>  
PMID: 30414908

**LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.**

Thurner, L., Hartmann, S., Fadle, N., Kemele, M., Bock, T., Bewarder, M., Regitz, E., Neumann, F., Nimmegern, A., von Müller, L., Pott, C., Kim, Y.-J., Bohle, R.M., Wasik, M., Schuster, S.J., Hansmann, M.-L., Preuss, K.-D., Pfreundschuh, M., 2018a. *Leukemia*.

<https://doi.org/10.1038/s41375-018-0182-1>

PMID: 29955130

**Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL.**

Thurner, L., Preuss, K.-D., Bewarder, M., Kemele, M., Fadle, N., Regitz, E., Altmeyer, S., Schormann, C., Poeschel, V., Ziepert, M., Walter, S., Roth, P., Weller, M., Szczepanowski, M., Klapper, W., Monoranu, C., Rosenwald, A., Möller, P., Hartmann, S., Hansmann, M.-L., Mackensen, A., Schäfer, H., Schorb, E., Illerhaus, G., Buslei, R., Bohle, R.M., Stilgenbauer, S., Kim, Y.-J., Pfreundschuh, M., 2018b. *Blood*.

<https://doi.org/10.1182/blood-2018-03-836932>

PMID: 30249786

**Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, suppresses tumor growth in mice via impeding both angiogenesis and vascular permeability.**

Venugopal, S., Kao, C., Chandna, R., Sulochana, K.N., Subramanian, V., Chen, M., Kini, R.M., Ge, R., 2018. *Angiogenesis* 21, 653–665.

<https://doi.org/10.1007/s10456-018-9616-7>

**Estrogen abrogates zoledronic acid induced gene expression signature in endocrine sensitive tumor cell lines in vitro.**

Weingartshofer, S., Bilban, M., Kastner, M.T., Hlavaty, J., Walter, I., Grunt, T.W., Singer, C.F., 2018. *JCO* 36, e12570–e12570.

[https://doi.org/10.1200/JCO.2018.36.15\\_suppl.e12570](https://doi.org/10.1200/JCO.2018.36.15_suppl.e12570)

**Brazilin blocks catabolic processes in human osteoarthritic chondrocytes via inhibition of NFKB1/p50.**

Weinmann, D., Mueller, M., Walzer, S.M., Hobusch, G.M., Lass, R., Gahleitner, C., Viernstein, H., Windhager, R., Toegel, S., 2018. *J. Orthop. Res.* 36, 2431–2438.

<https://doi.org/10.1002/jor.24013>

PMID: 29704279

**The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma.**

Weiten, R., Müller, T., Schmidt, D., Steiner, S., Kristiansen, G., Müller, S.C., Ellinger, J., Syring, I., 2018. *Cancer Biomark* 21, 839–847.

<https://doi.org/10.3233/CBM-170757>

PMID: 29400661

**Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties.**

Załoski, M., Stanuch, K., Karcz, T., Hinz, S., Latacz, G., Szymańska, E., Schabikowski, J., Doróż-Płonka, A., Handzlik, J., Drabczyńska, A., Müller, C.E., Kieć-Kononowicz, K., 2018. *MedChemComm* 9, 951–962.  
<https://doi.org/10.1039/C8MD00070K>

**Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery.**

Zlabinger, K., Lukovic, D., Hemetsberger, R., Gugerell, A., Winkler, J., Mandic, L., Traxler, D., Spannauer, A., Wolbank, S., Zannoni, G., Kaun, C., Posa, A., Gyenes, A., Petrasi, Z., Petnehazy, Ö., Repa, I., Hofer-Warbinek, R., de Martin, R., Gruber, F., Charwat, S., Huber, K., Pavo, N., Pavo, I.J., Nyolczas, N., Kraitchman, D.L., Gyöngyösi, M., 2018. *Front Bioeng Biotechnol* 6, 35.  
<https://doi.org/10.3389/fbioe.2018.00035>  
PMID: 29670878; PMCID: PMC5893806

**Endothelialization of Polyethylene Terephthalate Treated in SO<sub>2</sub> Plasma Determined by the Degree of Material Cytotoxicity.**

Alenka Vesel, Nina Recek, Helena Motaln, Miran Mozetic, 2017. *Plasma* 1, 12–22.  
<https://doi.org/10.3390/plasma1010002>

**Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.**

Englinger, B., Kallus, S., Senkiv, J., Heilos, D., Gabler, L., van Schoonhoven, S., Terenzi, A., Moser, P., Pirker, C., Timelthaler, G., Jäger, W., Kowol, C.R., Heffeter, P., Grusch, M., Berger, W., 2017. *J Exp Clin Cancer Res* 36.  
<https://doi.org/10.1186/s13046-017-0592-3>  
PMID: 28882160; PMCID: PMC5590147

**Role of thiamine in Huntington's disease pathogenesis: In vitro studies.**

Gruber, B., Krzysztoń-Russjan, J., Bubko, I., Syska, J., Jaworska, M., Zmysłowski, A., Rosłon, M., Drozd, J., Drozd, E., Majorczyk, E., Anuszewska, E., 2017. *Advances in Clinical and Experimental Medicine* 26, 751–760.  
<https://doi.org/10.17219/acem/63091>

**Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.**

Gschwantler-Kaulich, D., Weingartshofer, S., Grunt, T.W., Mairhofer, M., Tan, Y., Gamper, J., Singer, C.F., 2017. *PLOS ONE* 12, e0185566.  
<https://doi.org/10.1371/journal.pone.0185566>

**In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines.**

Klameth, L., Rath, B., Hamilton, G., 2017. *Journal of Cancer* 8, 1733–1743.  
<https://doi.org/10.7150/jca.17816>

**Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition.**

Kubista, B., Schoefl, T., Mayr, L., van Schoonhoven, S., Heffeter, P., Windhager, R., Keppler, B.K., Berger, W., 2017. *Journal of Experimental & Clinical Cancer Research* 36, 52.

<https://doi.org/10.1186/s13046-017-0527-z>

**A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.**

Mayer, B., Karakhanova, S., Bauer, N., Liu, L., Zhu, Y., Philippov, P.P., Werner, J., Bazhin, A.V., 2017. *Naunyn-Schmiedeberg's Arch Pharmacol* 390, 1125–1134.

<https://doi.org/10.1007/s00210-017-1412-1>

**Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates.**

M. Hackl, C., Schoenhacker-Alte, B., M. Klose, M.H., Henke, H., S. Legina, M., A. Jakupec, M., Berger, W., K. Keppler, B., Brüggemann, O., Teasdale, I., Heffeter, P., Kandioller, W., 2017. *Dalton Transactions* 46, 12114–12124.

<https://doi.org/10.1039/C7DT01767G>

**Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E.**

Panchuk, R.R., Lehka, L.V., Terenzi, A., Matselyukh, B.P., Rohr, J., Jha, A.K., Downey, T., Kril, I.J., Herbacek, I., van Schoonhoven, S., Heffeter, P., Stoika, R.S., Berger, W., 2017. *Free Radical Biology and Medicine* 106, 134–147.

<https://doi.org/10.1016/j.freeradbiomed.2017.02.024>

**Neoadjuvant therapy for resectable pancreatic cancer.**

Rahman, S.H., Urquhart, R., Molinari, M., 2017. *World J Gastrointest Oncol* 9, 457–465.

<https://doi.org/10.4251/wjgo.v9.i12.457>

PMID: 29290916; PMCID: PMC5740086

**Phenylalanine derivatives with modulating effects on human  $\alpha$ 1-glycine receptors and anticonvulsant activity in strychnine-induced seizure model in male adult rats.**

Sadek, B., Oz, M., Nurulain, S.M., Jayaprakash, P., Latacz, G., Kieć-Kononowicz, K., Szymańska, E., 2017. *Epilepsy Res.* 138, 124–131.

<https://doi.org/10.1016/j.eplepsyres.2017.05.008>

PMID: 28554717

**Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis.**

Schoenhacker-Alte, B., Mohr, T., Pirker, C., Kryeziu, K., Kuhn, P.-S., Buck, A., Hofmann, T., Gerner, C., Hermann, G., Koellensperger, G., Keppler, B.K., Berger, W., Heffeter, P., 2017. *Cancer Lett.* 404, 79–88.

<https://doi.org/10.1016/j.canlet.2017.07.009>

PMID: 28716523

**The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.**

Syring, I., Weiten, R., Müller, T., Schmidt, D., Steiner, S., Kristiansen, G., Müller, S.C., Ellinger, J., 2017. *Anticancer Res.* 37, 6685–6695.

<https://doi.org/10.21873/anticancer.12127>

PMID: 29187445

**Platelet Lysate: The Better Choice for Jaw Periosteal Cell Mineralization.**

Wanner, Y., Umrath, F., Waidmann, M., Reinert, S., Alexander, D., 2017. *Stem Cells International* 2017, 1–10.

<https://doi.org/10.1155/2017/8303959>

**LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines.**

Aschacher, T., Wolf, B., Enzmann, F., Kienzl, P., Messner, B., Sampl, S., Svoboda, M., Mechtcheriakova, D., Holzmann, K., Bergmann, M., 2016. *Oncogene* 35, 94–104.

<https://doi.org/10.1038/onc.2015.65>

PMID: 25798839

**Toxicity of Nanoparticles and an Overview of Current Experimental Models.**

Bahadar, H., Maqbool, F., Niaz, K., Abdollahi, M., 2016. *Iran Biomed J* 20, 1–11.

<https://doi.org/10.7508/ibj.2016.01.001>

PMID: 26286636; PMCID: PMC4689276

**Intracellular glutathione level and efflux in human melanoma and cervical cancer cells differing in doxorubicin resistance.**

Drozd, E., Gruber, B., Marczevska, J., Drozd, J., Anuszevska, E., 2016. *Postępy Higieny i Medycyny Doświadczalnej* 70, 319–328.

<https://doi.org/10.5604/17322693.1199712>

**Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells.**

Hamilton, G., Rath, B., Holzer, S., Hochmair, M., 2016. *Transl Lung Cancer Res* 5, 71–77.

<https://doi.org/10.3978/j.issn.2218-6751.2015.12.12>

PMID: 26958494; PMCID: PMC4758977

**Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.**

Hoda, M.A., Pirker, C., Dong, Y., Schelch, K., Heffeter, P., Kryeziu, K., van Schoonhoven, S., Klikovits, T., Laszlo, V., Rozsas, A., Ozsvar, J., Klepetko, W., Döme, B., Grusch, M., Hegedüs, B., Berger, W., 2016. *Mol. Cancer Ther.* 15, 2357–2369.

<https://doi.org/10.1158/1535-7163.MCT-15-0846>

PMID: 27512118



**The Synthesis of 1,3,5-triazine Derivatives and JNJ7777120 Analogues with Histamine H4 Receptor Affinity and Their Interaction with PTEN Promoter.**

Latacz, G., Kechagioglou, P., Papi, R., Łażewska, D., Więcek, M., Kamińska, K., Wencel, P., Karcz, T., Schwed, J.S., Stark, H., Kyriakidis, D.A., Kieć-Kononowicz, K., 2016. *Chem Biol Drug Des* 88, 254–263.

<https://doi.org/10.1111/cbdd.12752>

PMID: 26931395

**Manually and automatically produced pellet cultures of human primary chondrocytes: A comparative analysis.**

Lehmann, Ricarda, Gallert, C., Roddelkopf, T., Junginger, S., Jonitz-Heincke, A., Wree, A., Thurow, K., 2016. *Engineering in Life Sciences* 16, 272–282.

<https://doi.org/10.1002/elsc.201500010>

**3 dimensional cell cultures: a comparison between manually and automatically produced alginate beads.**

Lehmann, R., Gallert, C., Roddelkopf, T., Junginger, S., Wree, A., Thurow, K., 2016. *Cytotechnology* 68, 1049–1062.

<https://doi.org/10.1007/s10616-015-9861-1>

PMID: 25842191; PMCID: PMC4960154

**Gemcitabine-loaded and antibody-tagged superparamagnetic iron oxide nanoparticles as targeted drug vehicles in pancreatic cancer cell lines.**

Nandi, S., Sykes, P.D., Hasan, E., Rubbi, C., Barrow, M., Neoptolemos, J.P., Costello, E., Rosseinsky, M., Halloran, C.M., 2016. *HPB* 18, e776.

<https://doi.org/10.1016/j.hpb.2016.01.306>

**Mitochondria do not play a major role in landomycin E-induced ROS burst and circumvention of multiple drug resistance in HL-60 leukemia cells.**

Panchuk, R.R., Lehka, L.V., Rohr, J., Berger, W., Stoika, R.S., 2016. *Biopolymers & Cell* 32, 190–202.

<https://doi.org/10.7124/bc.000920>

**Effects of inorganic phosphate and FGF23 on C2C12 myoblast cells.**

Raimann, A., Dangl, A., Javanmardi, A., Ertl, A., Egerbacher, M., Greber-Platzer, S., Haeusler, G., 2016. Presented at the 43rd Annual European Calcified Tissue Society Congress, BioScientifica.

<https://doi.org/10.1530/boneabs.5.P269>

**Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.**

Syring, I., Klümper, N., Offermann, A., Braun, M., Deng, M., Boehm, D., Queisser, A., von Mässenhausen, A., Brägelmann, J., Vogel, W., Schmidt, D., Majores, M., Schindler, A., Kristiansen, G., Müller, S.C., Ellinger, J., Shaikhibrahim, Z., Perner, S., 2016. *Oncotarget* 7, 23043–23055.

<https://doi.org/10.18632/oncotarget.8469>

PMID: 27050271; PMCID: PMC5029609

**Cell confluence induces switching from proliferation to migratory signaling by site-selective phosphorylation of PDGF receptors on lipid raft platforms.**

Szöőr, Á., Ujlaky-Nagy, L., Tóth, G., Szöllősi, J., Vereb, G., 2016. *Cell. Signal.* 28, 81–93.

<https://doi.org/10.1016/j.cellsig.2015.11.012>

PMID: 26631574

**Anabolic and anti-resorptive modulation of bone homeostasis by the epigenetic modulator sulforaphane, a naturally occurring isothiocyanate.**

Thaler, R., Maurizi, A., Roschger, P., Sturmlechner, I., Khani, F., Spitzer, S., Rumpler, M., Zwerina, J., Karlic, H., Dudakovic, A., Klaushofer, K., Teti, A., Rucci, N., Varga, F., Wijnen, A.J. van, 2016. *J. Biol. Chem.* jbc.M115.678235.

<https://doi.org/10.1074/jbc.M115.678235>

PMID: 26757819

**Coating of  $\beta$ -tricalcium phosphate scaffolds-a comparison between graphene oxide and poly-lactic-co-glycolic acid.**

Ardjomandi, N., Henrich, A., Huth, J., Klein, C., Schweizer, E., Scheideler, L., Rupp, F., Reinert, S., Alexander, D., 2015. *Biomed Mater* 10, 045018.

<https://doi.org/10.1088/1748-6041/10/4/045018>

PMID: 26238604

**Identification of novel long non-coding RNAs in clear cell renal cell carcinoma.**

Blondeau, J.J., Deng, M., Syring, I., Schrödter, S., Schmidt, D., Perner, S., Müller, S.C., Ellinger, J., 2015. *Clin Epigenetics* 7, 10.

<https://doi.org/10.1186/s13148-015-0047-7>

PMID: 25685243; PMCID: PMC4326488

**Cytotoxicity Evaluation and Crystallochemical Analysis of a Novel and Commercially Available Bone Substitute Material.**

Bojar, W., Ciach, T., Kucharska, M., Maurin, J., Gruber, B., Krzysztoń-Russjan, J., Bubko, I., Anuszczyńska, E., 2015. *Advances in Clinical and Experimental Medicine* 24, 511–516.

<https://doi.org/10.17219/acem/22599>

**Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors.**

Choong, E., Guo, J., Persson, A., Viriding, S., Johansson, I., Mkrtchian, S., Ingelman-Sundberg, M., 2015. *PLOS ONE* 10, e0122820.

<https://doi.org/10.1371/journal.pone.0122820>

**Synthetic alkyl substituted quinones oxidize membrane proteins and arrest *Plasmodium falciparum* growth in vitro.**

Duran Lengua, M., Kamali, A.N., Cano, A.J., Piermattey, J., Reyes, N., Bautista, J.M., Gaitan, R., 2015. *African Journal of Pharmacy and Pharmacology* 9, 595–602.

<https://doi.org/10.5897/AJPP2014.4257>

**Effects of non-toxic zinc exposure on human epidermal keratinocytes.**

Emri, E., Miko, E., Bai, P., Boros, G., Nagy, G., Rózsa, D., Juhász, T., Hegedűs, C., Horkay, I., Remenyik, É., Emri, G., 2015. *Metallomics* 7, 499–507.  
<https://doi.org/10.1039/C4MT00287C>

**Biological high throughput screening of 2D and 3D cell cultures for future industrial up-scaling.**

Gallert, C., Lehmann, R., Roddelkopf, T., Junginger, S., Thurow, K., 2015, in: *2015 IEEE International Conference on Automation Science and Engineering (CASE)*. Presented at the 2015 IEEE International Conference on Automation Science and Engineering (CASE), pp. 1527–1532.  
<https://doi.org/10.1109/CoASE.2015.7294316>

**Activin A is anti-lymphangiogenic in a melanoma mouse model.**

Heinz, M., Niederleithner, H.L., Puujalka, E., Soler-Cardona, A., Grusch, M., Pehamberger, H., Loewe, R., Petzelbauer, P., 2015. *J. Invest. Dermatol.* 135, 212–221.  
<https://doi.org/10.1038/jid.2014.328>  
PMID: 25084052

**Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.**

Miklos, W., Pelivan, K., Kowol, C.R., Pirker, C., Dornetshuber-Fleiss, R., Spitzwieser, M., Englinger, B., van Schoonhoven, S., Cichna-Markl, M., Koellensperger, G., Keppler, B.K., Berger, W., Heffeter, P., 2015. *Cancer Lett.* 361, 112–120.  
<https://doi.org/10.1016/j.canlet.2015.02.049>  
PMID: 25749419

**Balanced Hydroxyethylstarch (HES 130/0.4) Impairs Kidney Function In-Vivo without Inflammation.**

Schick, M.A., Baar, W., Bruno, R.R., Wollborn, J., Held, C., Schneider, R., Flemming, S., Schlegel, N., Roewer, N., Neuhaus, W., Wunder, C., 2015. *PLoS ONE* 10, e0137247.  
<https://doi.org/10.1371/journal.pone.0137247>  
PMID: 26340751; PMCID: PMC4560431

**EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.**

Sevelde, F., Mayr, L., Kubista, B., Lötsch, D., van Schoonhoven, S., Windhager, R., Pirker, C., Micksche, M., Berger, W., 2015. *Journal of Experimental & Clinical Cancer Research* 34, 134.  
<https://doi.org/10.1186/s13046-015-0251-5>

**The molecular basis for development of proinflammatory autoantibodies to progranulin.**

Thurner, L., Fadle, N., Regitz, E., Kemele, M., Klemm, P., Zaks, M., Stöger, E., Bette, B., Carbon, G., Zimmer, V., Assmann, G., Murawski, N., Kubuschok, B., Held, G., Preuss, K.-D., Pfreundschuh, M., 2015. *J. Autoimmun.* 61, 17–28.  
<https://doi.org/10.1016/j.jaut.2015.05.002>  
PMID: 26005049

**Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression.**

Wollborn, J., Wunder, C., Stix, J., Neuhaus, W., Bruno, R.R., Baar, W., Flemming, S., Roewer, N., Schlegel, N., Schick, M.A., 2015. *J Pharmacol Pharmacother* 6, 13–23.  
<https://doi.org/10.4103/0976-500X.149138>  
PMID: 25709347; PMCID: PMC4319242

**Synthesis and Analgesic Activity of Annelated Xanthine Derivatives in Experimental Models in Rodents.**

Zygmunt, M., Sapa, J., Drabczyńska, A., Karcz, T., Müller, C., Köse, M., Latacz, G., Schabikowski, J., Bednarski, M., Kieć-Kononowicz, K., 2015. *Arch. Pharm. (Weinheim)* 348, 704–714.  
<https://doi.org/10.1002/ardp.201500169>  
PMID: 26248713

**In toto differentiation of human amniotic membrane towards the Schwann cell lineage.**

Banerjee, A., Nürnberger, S., Hennerbichler, S., Riedl, S., Schuh, C.M.A.P., Hacobian, A., Teuschl, A., Eibl, J., Redl, H., Wolbank, S., 2014. *Cell Tissue Bank* 15, 227–239.  
<https://doi.org/10.1007/s10561-013-9401-1>  
PMID: 24166477

**Quinoid Compounds Cause Inhibition of Falcipain 2, and Arrest Plasmodium falciparum Growth in Vitro †.**

DURAN-LENGUA, M., SALAS-SARDUY, E., CANO-DURAN, L.M., MONERIZ-PRETELL, C.E., MÉNDEZ-CUADRO, D.M., LORENZO-RIVERA, J., PIERMATTEY-DITTA, J., MONTALVO-ACOSTA, J., CRUZ, J.M.B.-S., IBARRA, R.G., 2014. *Latin American Journal of Pharmacy* 9

**The study of cellular cytotoxicity of argireline - an anti-aging peptide.**

Grosicki, M., Latacz, G., Szopa, A., Cukier, A., Kieć-Kononowicz, K., 2014. *Acta Biochimica Polonica* 61

**Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines.**

Hamilton, G., Klameth, L., Rath, B., Thalhammer, T., 2014. *Molecules* 19, 2077–2088.  
<https://doi.org/10.3390/molecules19022077>  
PMID: 24549232; PMCID: PMC6271949

**Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes.**

Holmgren, G., Sjögren, A.-K., Barragan, I., Sabirsh, A., Sartipy, P., Synnergren, J., Björquist, P., Ingelman-Sundberg, M., Andersson, T.B., Edsbacke, J., 2014. *Drug Metab. Dispos.* 42, 1401–1406.

<https://doi.org/10.1124/dmd.114.059154>

PMID: 24980256

**Combination therapy using a novel Plk-1 inhibitor and gemcitabine in pancreatic cancer cells.**

Jones, O., Greenhalf, W. (Bill), Halloran, C., Ghaneh, P., 2014. *Pancreatology* 14, S21.

<https://doi.org/10.1016/j.pan.2014.05.444>

PMID: 24555975, 24555975

**Storage and qualification of viable intact human amniotic graft and technology transfer to a tissue bank.**

Laurent, R., Nallet, A., Obert, L., Nicod, L., Gindraux, F., 2014. *Cell Tissue Bank* 15, 267–275.

<https://doi.org/10.1007/s10561-014-9437-x>

PMID: 24633398

**Intact human amniotic membrane differentiated towards the chondrogenic lineage.**

Lindenmair, A., Nürnberger, S., Stadler, G., Meinl, A., Hackl, C., Eibl, J., Gabriel, C., Hennerbichler, S., Redl, H., Wolbank, S., 2014. *Cell Tissue Bank* 15, 213–225.

<https://doi.org/10.1007/s10561-014-9454-9>

PMID: 24828570

**Autophagy mediates resistance to gemcitabine treatment through a novel E2F1-p300-VMP1 pathway.**

Vaccaro, M.I., Ropolo, A., Molejon, M.I., Catrinacio, C., Renna, F., Boggio, V., Gonzalez, C., 2014. *Pancreatology* 14, S21.

<https://doi.org/10.1016/j.pan.2014.05.443>

PMID: 24555975

**Influence of interferon- $\alpha$  on the expression of the cancer stem cell markers in pancreatic carcinoma cells.**

Zhu, Y., Karakhanova, S., Huang, X., Deng, S. ping, Werner, J., Bazhin, A.V., 2014. *Experimental Cell Research* 324, 146–156.

<https://doi.org/10.1016/j.yexcr.2014.03.020>

**Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.**

Kryeziu, K., Jungwirth, U., Hoda, M.A., Ferk, F., Knasmüller, S., Karnthaler-Benbakka, C., Kowol, C.R., Berger, W., Heffeter, P., 2013. *Mol. Cancer Ther.* 12, 1073–1084.

<https://doi.org/10.1158/1535-7163.MCT-13-0065>

PMID: 23548265

**Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.**

Travica, S., Pors, K., Loadman, P.M., Shnyder, S.D., Johansson, I., Alandas, M.N., Sheldrake, H.M., Mkrtchian, S., Patterson, L.H., Ingelman-Sundberg, M., 2013. *Clin. Cancer Res.* 19, 2952–2961.  
<https://doi.org/10.1158/1078-0432.CCR-13-0238>  
PMID: 23589180

**Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells.**

Zwick, C., Fadle, N., Regitz, E., Kemele, M., Stilgenbauer, S., Bühler, A., Pfreundschuh, M., Preuss, K.-D., 2013. *Blood* 121, 4708–4717.  
<https://doi.org/10.1182/blood-2012-08-447904>  
PMID: 23580660

**Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.**

Cao, R., Ji, H., Feng, N., Zhang, Y., Yang, X., Andersson, P., Sun, Y., Tritsaris, K., Hansen, A.J., Dissing, S., Cao, Y., 2012. *Proc. Natl. Acad. Sci. U.S.A.* 109, 15894–15899.  
<https://doi.org/10.1073/pnas.1208324109>  
PMID: 22967508; PMCID: PMC3465417

**Anticancer activity of methyl-substituted oxaliplatin analogs.**

Jungwirth, U., Xanthos, D.N., Gojo, J., Bytzek, A.K., Körner, W., Heffeter, P., Abramkin, S.A., Jakupec, M.A., Hartinger, C.G., Windberger, U., Galanski, M., Keppler, B.K., Berger, W., 2012. *Mol. Pharmacol.* 81, 719–728.  
<https://doi.org/10.1124/mol.111.077321>  
PMID: 22331606; PMCID: PMC3375001

**MET expression in melanoma correlates with a lymphangiogenic phenotype.**

Swoboda, A., Schanab, O., Tauber, S., Bilban, M., Berger, W., Petzelbauer, P., Mikula, M., 2012. *Hum. Mol. Genet.* 21, 3387–3396.  
<https://doi.org/10.1093/hmg/dds171>  
PMID: 22570180

**Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.**

Breinig, M., Mayer, P., Harjung, A., Goepfert, B., Malz, M., Penzel, R., Neumann, O., Hartmann, A., Dienemann, H., Giaccone, G., Schirmacher, P., Kern, M.A., Chiosis, G., Rieker, R.J., 2011. *Clin. Cancer Res.* 17, 2237–2249.  
<https://doi.org/10.1158/1078-0432.CCR-10-1689>  
PMID: 21372220

**Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells.**

Ang, C.W., Nedjadi, T., Sheikh, A.A., Tweedle, E.M., Tonack, S., Honap, S., Jenkins, R.E., Park, B.K., Schwarte-Waldhoff, I., Khattak, I., Azadeh, B., Dodson, A., Kalirai, H., Neoptolemos, J.P., Rooney, P.S., Costello, E., 2010. *Carcinogenesis* 31, 1541–1551.

<https://doi.org/10.1093/carcin/bgq137>

PMID: 20622003

**Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative.**

Cindric, M., Cipak, A., Serly, J., Plotniece, A., Jaganjac, M., Mrakovcic, L., Lovakovic, T., Dedic, A., Soldo, I., Duburs, G., Zarkovic, N., Molnár, J., 2010. *Anticancer Res.* 30, 4063–4069

PMID: 21036720

**Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.**

Gomez, A., Nekvindova, J., Travica, S., Lee, M.-Y., Johansson, I., Edler, D., Mkrtchian, S., Ingelman-Sundberg, M., 2010. *Mol. Pharmacol.* 78, 1004–1011.

<https://doi.org/10.1124/mol.110.067652>

PMID: 20805301

**Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.**

Shehata, M., Schnabl, S., Demirtas, D., Hilgarth, M., Hubmann, R., Ponath, E., Badrnya, S., Lehner, C., Hoelbl, A., Duechler, M., Gaiger, A., Zielinski, C., Schwarzmeier, J.D., Jaeger, U., 2010. *Blood* 116, 2513–2521.

<https://doi.org/10.1182/blood-2009-10-248054>

PMID: 20576813

**The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls.**

Vercauteren, D., Vandenbroucke, R.E., Jones, A.T., Rejman, J., Demeester, J., De Smedt, S.C., Sanders, N.N., Braeckmans, K., 2010. *Mol. Ther.* 18, 561–569.

<https://doi.org/10.1038/mt.2009.281>

PMID: 20010917; PMCID: PMC2839427

**Induction of endostatin expression in meniscal fibrochondrocytes by co-culture with endothelial cells.**

Hoberg, M., Schmidt, E.L., Tuerk, M., Stark, V., Aicher, W.K., Rudert, M., 2009. *Archives of Orthopaedic and Trauma Surgery* 129, 1137–1143.

<https://doi.org/10.1007/s00402-008-0766-8>

**NF-kappaB independent activation of a series of proinflammatory genes by hydrogen sulfide.**

Stuhlmeier, K.M., Bröll, J., Iliev, B., 2009. *Exp. Biol. Med. (Maywood)* 234, 1327–1338.

<https://doi.org/10.3181/0904-RM-137>

PMID: 19855074

**Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent.**

Walochnik, J., Obwaller, A., Gruber, F., Mildner, M., Tschachler, E., Suchomel, M., Duchêne, M., Auer, H., 2009. *J. Antimicrob. Chemother.* 64, 539–545.

<https://doi.org/10.1093/jac/dkp215>

PMID: 19549672

**Differential effects of rapamycin in anti-GBM glomerulonephritis.**

Hochegger, K., Jansky, G.L., Soleiman, A., Wolf, A.M., Tagwerker, A., Seger, C., Griesmacher, A., Mayer, G., Rosenkranz, A.R., 2008. *J. Am. Soc. Nephrol.* 19, 1520–1529.

<https://doi.org/10.1681/ASN.2007121375>

PMID: 18480312; PMCID: PMC2488269

**FGF18 in colorectal tumour cells: autocrine and paracrine effects.**

Sonvilla, G., Allerstorfer, S., Stättner, S., Karner, J., Klimpfinger, M., Fischer, H., Grasl-Kraupp, B., Holzmann, K., Berger, W., Wrba, F., Marian, B., Grusch, M., 2008. *Carcinogenesis* 29, 15–24.

<https://doi.org/10.1093/carcin/bgm202>

PMID: 17890768

**The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways.**

Demyanets, S., Kaun, C., Rychli, K., Rega, G., Pfaffenberger, S., Afonyushkin, T., Bochkov, V.N., Maurer, G., Huber, K., Wojta, J., 2007. *Am. J. Physiol. Heart Circ. Physiol.* 293, H1962–1968.

<https://doi.org/10.1152/ajpheart.01366.2006>

PMID: 17604327

**SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.**

Emanuele, S., Lauricella, M., Carlisi, D., Vassallo, B., D'Anneo, A., Di Fazio, P., Vento, R., Tesoriere, G., 2007. *Apoptosis* 12, 1327–1338.

<https://doi.org/10.1007/s10495-007-0063-y>

PMID: 17351739

**Opposite regulation of IL-1beta and secreted IL-1 receptor antagonist production by phosphatidylinositide-3 kinases in human monocytes activated by lipopolysaccharides or contact with T cells.**

Molnarfi, N., Gruaz, L., Dayer, J.-M., Burger, D., 2007. *J. Immunol.* 178, 446–454

PMID: 17182583



**Dioxin affects glucose transport via the arylhydrocarbon receptor signal cascade in pluripotent embryonic carcinoma cells.**

Tonack, S., Kind, K., Thompson, J.G., Wobus, A.M., Fischer, B., Santos, A.N., 2007. *Endocrinology* 148, 5902–5912.

<https://doi.org/10.1210/en.2007-0254>

PMID: 17872374

**Structure and in vitro cytocompatibility of the gastropod shell of *Helix pomatia*.**

Bächle, M., Hübner, U., Kohal, R.J., Han, J.S., Wiedmann-Al-Ahmad, M., 2006. *Tissue Cell* 38, 337–344.

<https://doi.org/10.1016/j.tice.2006.08.004>

PMID: 17010402

**Structure-activity profiles of Ab-derived TNF fusion proteins.**

Bauer, S., Adrian, N., Fischer, E., Kleber, S., Stenner, F., Wadle, A., Fadle, N., Zoellner, A., Bernhardt, R., Knuth, A., Old, L.J., Renner, C., 2006. *J. Immunol.* 177, 2423–2430

PMID: 16888004

**Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.**

Fineschi, S., Reith, W., Guerne, P.A., Dayer, J.-M., Chizzolini, C., 2006. *FASEB J.* 20, 562–564.

<https://doi.org/10.1096/fj.05-4870fje>

PMID: 16410344

**The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the “clinically non-functioning” pituitary adenomas in vitro.**

Gruszka, A., Kunert-Radek, J., Radek, A., Pisarek, H., Taylor, J., Dong, J.Z., Culler, M.D., Pawlikowski, M., 2006. *Life Sci.* 78, 689–693.

<https://doi.org/10.1016/j.lfs.2005.05.061>

PMID: 16115652

**Influence of Cyclosporin A on human gingival keratinocytes in vitro.**

Lauer, G., Mai, R., Pradel, W., Proff, P., Gedrange, T., Beyer, J., 2006. *J Craniomaxillofac Surg* 34 Suppl 2, 116–122.

[https://doi.org/10.1016/S1010-5182\(06\)60024-3](https://doi.org/10.1016/S1010-5182(06)60024-3)

PMID: 17071404

**Antiviral activity of cycloaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses.**

Meerbach, A., Meier, C., Sauerbrei, A., Meckel, H.-M., Wutzler, P., 2006. *Int. J. Antimicrob. Agents* 27, 423–430.

<https://doi.org/10.1016/j.ijantimicag.2005.11.021>

PMID: 16621459

**Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.**

Perabo, F.G.E., Frössler, C., Landwehrs, G., Schmidt, D.H., von Rücker, A., Wirger, A., Müller, S.C., 2006. *Anticancer Res.* 26, 2129–2135  
PMID: 16827155

**Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice.**

Tepel, J., Dagvadorj, O., Kapischke, M., Sipos, B., Leins, A., Kremer, B., Kalthoff, H., 2006. *Int J Colorectal Dis* 21, 365–372.

<https://doi.org/10.1007/s00384-005-0013-5>

PMID: 16133009

**A soluble 17 kDa tumour necrosis factor (TNF) mutein, TNF-SAM2, with membrane-bound TNF-like biological characteristics.**

Yoshida, A., Kohchi, C., Inagawa, H., Nishizawa, T., Hori, H., Soma, G.-I., 2006. *Anticancer Res.* 26, 4003–4007

PMID: 17195449

**Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2.**

Ank, N., Petersen, K., Malmgaard, L., Mogensen, S.C., Paludan, S.R., 2005. *J. Virol.* 79, 9831–9841.

<https://doi.org/10.1128/JVI.79.15.9831-9841.2005>

PMID: 16014944; PMCID: PMC1181601

**Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).**

Heffeter, P., Pongratz, M., Steiner, E., Chiba, P., Jakupec, M.A., Elbling, L., Marian, B., Körner, W., Sevela, F., Micksche, M., Keppler, B.K., Berger, W., 2005. *J. Pharmacol. Exp. Ther.* 312, 281–289.

<https://doi.org/10.1124/jpet.104.073395>

PMID: 15331656

**Biological Characterization of Novel Inhibitors of the Gram-Positive DNA Polymerase IIIC Enzyme.**

Kuhl, A., Svenstrup, N., Ladel, C., Otteneder, M., Binas, A., Schiffer, G., Brands, M., Lampe, T., Ziegelbauer, K., Rübsamen-Waigmann, H., Haebich, D., Ehlert, K., 2005. *Antimicrob. Agents Chemother.* 49, 987–995.

<https://doi.org/10.1128/AAC.49.3.987-995.2005>

PMID: 15728893

**Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis.**

Sulochana, K.N., Fan, H., Jois, S., Subramanian, V., Sun, F., Kini, R.M., Ge, R., 2005. *J. Biol. Chem.* 280, 27935–27948.

<https://doi.org/10.1074/jbc.M414320200>

PMID: 15923192

**Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells.**

Wegner, B., Baer, P., Gauer, S., Oremek, G., Hauser, I.A., Geiger, H., 2005. *Nephrol. Dial. Transplant.* 20, 2071–2079.

<https://doi.org/10.1093/ndt/gfh948>

PMID: 15998654

**Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein.**

Bauer, S., Adrian, N., Williamson, B., Panousis, C., Fadle, N., Smerd, J., Fettah, I., Scott, A.M., Pfreundschuh, M., Renner, C., 2004. *J. Immunol.* 172, 3930–3939

PMID: 15004201

**Toxicological and Pharmacological Evaluation of New Drug Candidates by in Vitro Robotic High-Throughput Cell Assays.**

Thurow, K., Entzian, K., Eberlein, G., 2004. *JALA: Journal of the Association for Laboratory Automation* 9, 159–162.

<https://doi.org/10.1016/j.jala.2004.04.009>

**Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.**

Verhulst, A., D'Haese, P.C., De Broe, M.E., 2004. *J. Am. Soc. Nephrol.* 15, 2249–2257.

<https://doi.org/10.1097/01.ASN.0000136778.32499.05>

PMID: 15339974

**Construction of a functional S-layer fusion protein comprising an immunoglobulin G-binding domain for development of specific adsorbents for extracorporeal blood purification.**

Völlenklee, C., Weigert, S., Ilk, N., Egelseer, E., Weber, V., Loth, F., Falkenhagen, D., Sleytr, U.B., Sára, M., 2004. *Appl. Environ. Microbiol.* 70, 1514–1521

PMID: 15006773; PMCID: PMC368406

**Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury.**

Hutter, R., Sauter, B.V., Reis, E.D., Roque, M., Vorchheimer, D., Carrick, F.E., Fallon, J.T., Fuster, V., Badimon, J.J., 2003. *Circulation* 107, 1658–1663.

<https://doi.org/10.1161/01.CIR.0000058169.21850.CE>

PMID: 12668502

**Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.**

Sturlan, S., Baumgartner, M., Roth, E., Bachleitner-Hofmann, T., 2003. *Blood* 101, 4990–4997.

<https://doi.org/10.1182/blood-2002-08-2391>

PMID: 12609832

**Oxytocin stimulates proliferation of human osteoblast-like cells.**

Petersson, M., Lagumdzija, A., Stark, A., Bucht, E., 2002. *Peptides* 23, 1121–1126.

[https://doi.org/10.1016/S0196-9781\(02\)00041-4](https://doi.org/10.1016/S0196-9781(02)00041-4)

**Different effects of conjugated linoleic acid isomers on lipoprotein lipase activity in 3T3-L1 adipocytes.**

Lin, Y., Kreeft, A., Schuurbiens, J.A.E., Draijer, R., 2001. *The Journal of Nutritional Biochemistry* 12, 183–189.

[https://doi.org/10.1016/S0955-2863\(00\)00155-8](https://doi.org/10.1016/S0955-2863(00)00155-8)

**In vitro toxicity of surfactants in U937 cells: Cell membrane integrity and mitochondrial function.**

Jelinek, A., Klöcking, H.-P., 1998. *Experimental and Toxicologic Pathology* 50, 472–476.

[https://doi.org/10.1016/S0940-2993\(98\)80036-5](https://doi.org/10.1016/S0940-2993(98)80036-5)